Patients with multiple myeloma over a large catchment of 2.5 million square kilometres: a Western Australia retrospective survival review

2020 ◽  
Vol 50 (7) ◽  
pp. 869-872
Author(s):  
Teng Fong Ng ◽  
Sally Burrow ◽  
Michael Leahy ◽  
Bradley Augustson ◽  
Kevin Trentino ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Western Australia ◽  
Large Catchment

INCIDENCE AND OUTCOME OF MULTIPLE MYELOMA IN WESTERN AUSTRALIA, 1960 TO 1984

1988 ◽  
Vol 18 (6) ◽  
pp. 774-779 ◽  
Author(s):  
A. NANDAKUMAR ◽  
D. R. ENGLISH ◽  
L. E. DOUGAN ◽  
B. K. ARMSTRONG
Keyword(s):  
Multiple Myeloma ◽  
Western Australia

scholarly journals Survival of Patients with Multiple Myeloma in Western Australia, a Large State of 2.5 Million Square Kilometers: A Population Based Study

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 3552-3552
Author(s):  
Teng Fong Ng ◽  
Michael F. Leahy ◽  
Bradley Augustson ◽  
Sally Burrow ◽  
Philip Vlaskovsky ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Overall Survival ◽  
Western Australia ◽  
Survival Data ◽  
Conflicts Of Interest ◽  
Real Life ◽  
Public Hospitals ◽  
Capital City ◽  
Public Healthcare ◽  
Significant Difference

Abstract Background There has been concern that patients with malignant disease from remote and regional country areas may have adverse outcomes compared with those from cities. Western Australia (WA) with an area of 2,526,786 square kilometers, is one third the size of Australia. It has a population of 2.6 million of which 92% live in the capital city Perth and the southwest corner. In WA, multiple myeloma is managed in tertiary public hospitals and private physician practice located in Perth. While oral based immunomodulators and alkylators are readily delivered in the regional areas, patients travel to Perth for parenteral chemotherapy and stem cell transplantation. The WA state government subsidizes transport and accommodation for patients from regional areas to travel to Perth for treatment and clinical review via the Patient Assisted Travel Scheme (PATS). Telehealth through video conferencing is also used for review of patients on oral-based anti-myeloma treatment or during surveillance periods to avoid expensive and time-consuming travel to Perth. The Royal Flying Doctor Service (RFDS), a non-profit medical organization, provides prompt transfer of unwell patients from regional and remote areas of WA to Perth. Pathology services in remote regions are provided by the publicly funded PathWest organization. Method We retrospectively reviewed the survival outcomes of patients with multiple myeloma in the WA public healthcare system. Patients diagnosed between 2008 to 2017 were included (n=569). Staging information was extracted from the laboratory information system and the cytogenetic database in PathWest. Patient demographics, complications requiring admission, mortality and follow-up data were extracted from the public hospital patient management systems. Patients were segregated into regional or metropolitan by their residential address postcodes. Patients diagnosed and/or followed-up in the private sector were excluded. Survival was analyzed by Kaplan-Meier curves, Log-rank test and Cox proportional hazards model. Result Median age at diagnosis was 67 years old (range 29 to 98), with 56% above 65 years. 56% were males, 44% were females. Overall median survival was 46 months (95%CI:41,52). 1-year, 3-years and 5-years survival rates were 80%, 56% and 30% respectively. 25% (n=143) of patients resided in regional areas. No statistically significant difference in overall survival time between patients from metropolitan and regional areas was identified (p=0.2): 47 months (95% CI:43,54) and 42 months (95% CI: 33,54) respectively. Subgroup analysis also did not find any significant difference in overall survival of each R-ISS staging between metropolitan and regional areas. Discussion This retrospective study provides real-life survival data of of an Australian-based population in a state with a large land mass and low population density outside the capital city. The overall survival of patients living in regional areas was not significantly different from those living in the capital city. This gives credence to the benefit of the WA government supported regional network of travel, accommodation and Telehealth conferencing overcoming the distance barrier in the provision of comprehensive medical care in the management of a hematological malignancy. Figure. Figure. Disclosures No relevant conflicts of interest to declare.

Proteasome inhibitors as therapeutics

2005 ◽  
Vol 41 ◽  
pp. 205-218
Author(s):  
Constantine S. Mitsiades ◽  
Nicholas Mitsiades ◽  
Teru Hideshima ◽  
Paul G. Richardson ◽  
Kenneth C. Anderson
Keyword(s):  
Multiple Myeloma ◽  
Drug Class ◽  
Proteasome Inhibitors ◽  
Cell Cycle Regulators ◽  
Current State ◽  
Intracellular Mechanism ◽  
Ubiquitin Proteasome ◽  
Proteasome Pathway ◽  
Hodgkin's Lymphomas ◽  
Clinical Research Data

The ubiquitin–proteasome pathway is a principle intracellular mechanism for controlled protein degradation and has recently emerged as an attractive target for anticancer therapies, because of the pleiotropic cell-cycle regulators and modulators of apoptosis that are controlled by proteasome function. In this chapter, we review the current state of the field of proteasome inhibitors and their prototypic member, bortezomib, which was recently approved by the U.S. Food and Drug Administration for the treatment of advanced multiple myeloma. Particular emphasis is placed on the pre-clinical research data that became the basis for eventual clinical applications of proteasome inhibitors, an overview of the clinical development of this exciting drug class in multiple myeloma, and a appraisal of possible uses in other haematological malignancies, such non-Hodgkin's lymphomas.

Bone sialoprotein mRNA and protein expression in human multiple myeloma cell lines and patients

2000 ◽  
Vol 111 (4) ◽  
pp. 1118-1121 ◽  
Author(s):  
A. Bellahcene ◽  
I. Van Riet ◽  
C. de Greef ◽  
N. Antoine ◽  
M. F. Young ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Protein Expression ◽  
Cell Lines ◽  
Myeloma Cell ◽  
Bone Sialoprotein ◽  
Multiple Myeloma Cell ◽  
Human Multiple Myeloma ◽  
Mrna And Protein Expression

Absence Of Human Herpesvirus 8 Dna Sequences In Leucapheresis Products And Bone Marrow Samples Of Patients With Advanced Multiple Myeloma

2000 ◽  
Vol 109 (3) ◽  
pp. 676-677 ◽  
Author(s):  
R. Beck ◽  
F. Neipel ◽  
B. Canji ◽  
H. Hebart ◽  
L. Kanz ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Dna Sequences ◽  
Human Herpesvirus ◽  
Human Herpesvirus 8 ◽  
Herpesvirus 8

Continuous low-dose dexamethasone in relapsed or refractory multiple myeloma

2000 ◽  
Vol 111 (1) ◽  
pp. 381-381 ◽  
Author(s):  
C. W. Tiplady ◽  
G. P. Summerfield
Keyword(s):  
Multiple Myeloma ◽  
Low Dose ◽  
Refractory Multiple Myeloma

Controversies surrounding the clonogenic origin of multiple myeloma

2000 ◽  
Vol 110 (1) ◽  
pp. 240-241 ◽  
Author(s):  
Faith E. Davies ◽  
Andrew C. Rawstron ◽  
Roger G. Owen ◽  
Gareth J. Morgan
Keyword(s):  
Multiple Myeloma

Sturge-Weber syndrome and multiple myeloma

1969 ◽  
Vol 100 (4) ◽  
pp. 488b-488
Author(s):  
H. O. Curth
Keyword(s):  
Multiple Myeloma ◽  
Weber Syndrome ◽  
Sturge Weber Syndrome
Sign in / Sign up

Export Citation Format

Share Document